PharmiWeb.com - Global Pharma News & Resources

Press Releases - 2022-05-02

Date Title Company
02-May-2022 Artificial Eyes Market Is Expected To See Remarkable Growth In The Forecast Period Due To Increasing Number Demand By A Large Number Of Patient Population: Fact.MR MARKITWIRED Latest Market Reports
02-May-2022 Asia-Pacific Market For Carbapenem-Resistant Enterobacteriaceae Testing Is Expected To Expand During 2022-2032 MARKITWIRED Latest Market Reports
02-May-2022 High-Sensitivity Cardiac Biomarker Market Is Expected To Be A Growing Market Over The Forecast Period 2022-2032 MARKITWIRED Latest Market Reports
02-May-2022 OSE Immunotherapeutics Announces New European Patent Granted Covering CLEC-1, Novel Myeloid Immune Checkpoint Target For Cancer Immunotherapy Businesswire
02-May-2022 Europe Is Expected To Witness Significant Growth In The Global Market As The Adoption Of Nerve Ablation Devices Among Patient And Healthcare Professionals Has Increased MARKITWIRED Latest Market Reports
02-May-2022 Asia Pacific Is Expected To Register Growth During The Forecast Period As Several Companies Are Working On Supplying Customised Veterinary Tables: Fact.MR Report MARKITWIRED Latest Market Reports
02-May-2022 North America Pressure Infusion Cuffs Market Is Expected To Generate Sluggish Growth Owing To Saturation With The U.S. Leading The Market: Fact.MR Report MARKITWIRED Latest Market Reports
02-May-2022 NEXEL Earns the First ISO/IEC 17025:2017 Accreditation for iPSC-derived Cardiomyocyte-based Cardiac Safety Testing Businesswire
02-May-2022 Europäische Kommission erteilt UPLIZNA® (Inebilizumab) die Zulassung zur Behandlung von Erwachsenen mit Neuromyelitis-optica-Spektrum-Erkrankungen (NMOSD) Businesswire
02-May-2022 Horizon Therapeutics plc reçoit l’approbation de la Commission européenne (CE) pour UPLIZNA® (inébilizumab) dans le traitement des adultes atteints de troubles du spectre de la neuromyélite optique (NMOSD) Businesswire
02-May-2022 Horizon Therapeutics riceve l’approvazione della Commissione europea (CE) per inebilizumab per il trattamento di adulti affetti da disturbo dello spettro della neuromielite ottica (NMOSD) Businesswire
02-May-2022 Horizon Therapeutics plc Receives European Commission (EC) Approval of UPLIZNA® (inebilizumab) for the Treatment of Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD) Businesswire
02-May-2022 Biotest AG: Biotest Supervisory Board appoints new Management Board member Biotest AG
02-May-2022 Demand For Atherosclerosis Drugs Market To Witness An Outstanding Growth By 2027 | Fact.MR Study MARKITWIRED Latest Market Reports
02-May-2022 Cardiac Ablation Technologies Market Is Representing A Y-O-Y Increase Of 11.1% During 2022-2032 | Fact.MR study MARKITWIRED Latest Market Reports
02-May-2022 Demand For Asthma Treatment Market To Witness An Outstanding Growth By 2027 | Fact.MR Study MARKITWIRED Latest Market Reports
02-May-2022 Demand For Canes and Crutches Market To Witness An Outstanding Growth By 2027 | Fact.MR Study MARKITWIRED Latest Market Reports
02-May-2022 Demand For Benign Prostatic Hyperplasia Treatment Market To Witness An Outstanding Growth By 2027 | Fact.MR Study MARKITWIRED Latest Market Reports
02-May-2022 Demand For Anti-Aging And Anti-Wrinkle Products Market To Witness An Outstanding Growth By 2027 | Fact.MR Study MARKITWIRED Latest Market Reports
02-May-2022 Ambulance Cots Market To Witness An Outstanding Growth By 2029 | Fact.MR Study MARKITWIRED Latest Market Reports